Drugs in MeSH Category Dopamine Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	8,846,074		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	8,414,922		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		DISCN	Yes	No	9,283,219		Y
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	10,449,146
Satsuma Pharms	ATZUMI	dihydroergotamine mesylate	POWDER;NASAL	217901-001	Apr 30, 2025		RX	Yes	Yes	10,792,253		Y
Amneal	BREKIYA (AUTOINJECTOR)	dihydroergotamine mesylate	SOLUTION;SUBCUTANEOUS	215400-001	May 14, 2025		RX	Yes	Yes	12,533,351		Y

Patent landscape and market dynamics for Dopamine Agonists (NLM MeSH): exclusivity, Orange Book status, and generic entry risks

Last updated: July 16, 2026

Dopamine agonists as a class face overlapping exclusivity and patent protection across Parkinson’s disease and restless legs syndrome (RLS). Competitive pressure is driven by (1) loss of composition-of-matter exclusivity for several older brands, (2) formulation and method-of-use patenting that can extend entry barriers, and (3) device or delivery-platform constraints for certain liquid and extended-release products. For investors and licensing teams, the main risk is not the headline active ingredient patent expiration, but later-granted patents tied to extended-release formulations, crystalline forms, specific dosing regimens, and combination products.

This market overview maps the patent strategy that dominates dopamine agonists and the commercial fault lines that typically determine when generics, authorized generics, or reformulations can enter.

---

Which dopamine agonists dominate the MeSH market and where is exclusivity concentrating?

Dopamine agonists in MeSH largely break into:

• Non-ergot dopamine agonists for Parkinson’s disease (PD): pramipexole, ropinirole, rotigotine, apomorphine.
• Ergot-derived dopamine agonists (historically key): bromocriptine.
• Dopamine agonists for RLS: pramipexole (IR/ER where applicable), ropinirole (IR/ER), rotigotine transdermal, and apomorphine in specific off-label or specialized contexts.
• Combination and adjunct products: dopamine agonist plus other agents, where method-of-use and combination formulation patents often extend.

Across these, the patent estate typically concentrates in:

1. Composition-of-matter and salts/crystalline forms for newer entrants.
2. Extended-release technology (matrix, osmotic, layered tablet systems).
3. Formulation stability patents (controlled release, bioavailability, pH-dependent dissolution).
4. Method-of-use claims tied to dosing schedules, switching regimens, and titration strategies.
5. Device-associated claims for transdermal delivery (for rotigotine-like platforms).

---

How do exclusivity timelines usually work for dopamine agonists in the US?

Exclusivity in the US is a combination of:

• Patent term (including PTA and any term adjustments).
• Regulatory exclusivity (typically 5-year new chemical entity / new molecular entity where applicable, 3-year for new formulations, and 7-year for orphan indications where relevant).
• Orange Book-listed patent claims for each approved NDA.

In practice for dopamine agonists:

• Older products (first-wave approvals of pramipexole, ropinirole, bromocriptine, and rotigotine) are usually in later patent lives, with generics focusing on clearance via ANDA certification and Paragraph IV challenges against specific Orange Book patents.
• Newer entrants and lifecycle extensions push the exclusivity “cliff” out via formulation patents and method-of-use claims that still require certification work.
• Extended-release and transdermal products tend to have more “surviving” patent coverage because technical differentiators are easier to claim than simple ingredient changes.

Featured snippet answer: For dopamine agonists, generics typically clear after the last Orange Book-listed patent covering the specific dosage form expires, which is often a formulation or method-of-use patent rather than the base active ingredient patent.

---

What patents protect dopamine agonist products: composition-of-matter vs formulation vs method-of-use?

Dopamine agonist patenting patterns by claim type:

Composition-of-matter and salt/crystal form

• Targets the active ingredient, its salts, solvates, hydrates, and polymorphs.
• Usually the earliest filing dates.
• Often expired or near-expiry for mature molecules in major markets.

Formulation and controlled-release

• Covers release rate profiles, polymers, excipient systems, and manufacturing constraints.
• Extended-release tablet and transdermal patches tend to have the densest formulation claims.
• These patents can outlast composition-of-matter, shifting generic launch timing.

Method-of-use and dosing regimens

• Claims can cover titration schedules, conversion between dosing forms, or specific patient subsets.
• Even when the molecule is off-patent, the method-of-use can delay certain label-based generic strategies, including where a generic seeks to rely on different dosing recommendations.

Delivery system/device patents

• Transdermal systems and patch attachment, membrane designs, and drug-in-adhesive structures can be claim-heavy.
• These claims often create a practical barrier beyond standard ANDA bioequivalence.

Market implication: The “last patent standing” is frequently an extended-release or delivery-system patent.

---

What is the Orange Book status of key dopamine agonists, and which patent claims typically block ANDAs?

For US market entry planning, the practical workflow for dopamine agonists is:

1. Identify the approved product (NDA/ANDA listing).
2. Pull Orange Book patents for that specific strength/dosage form.
3. Determine claim expiration dates for each listed patent.
4. Run ANDA Paragraph IV or carve-out strategies (for some products) against specific patents.

Across dopamine agonists, the patents most likely to block an ANDA launch are:

• Formulation patents that cover the specific release profile.
• Pharmacokinetic performance claims tied to in vivo release behavior.
• Manufacturing method patents where the process is linked to the claim scope.
• Method-of-use patents that are tied to label-specific regimens.

Featured snippet answer: The Orange Book “patent clock” for dopamine agonists is often dominated by formulation and delivery-system claims, not only by base active ingredient patents.

---

When does each dopamine agonist lose exclusivity: how to think about the “last Orange Book patent” date?

A reliable market dynamic is that generic timing tracks the last patent for the exact NDA strength and dosage form, including:

• Expiration of the latest composition/formulation claim.
• Expiration of pediatric exclusivity (if any) tied to that NDA.
• Expiration of orphan exclusivity (if any) tied to that indication.

For dopamine agonists:

• Extended-release products usually retain the latest formulation patents.
• Transdermal products often have the latest delivery-system patents.
• RLS and PD label differences can create separate exclusivity windows when claims are indication-specific.

Business outcome: Launch dates in the dopamine agonist class are most sensitive to which patents are listed for the exact marketed form and strength, and which ones survive litigation or are design-around successfully.

---

Which companies are challenging dopamine agonist patents through Paragraph IV ANDAs?

In US practice, Paragraph IV filings for dopamine agonists usually come from:

• Mid-size generic companies that specialize in lifecycle challenges.
• Large generics that can litigate and absorb settlement risk.
• Authorized generic entrants that reduce market disruption from full competition.

The highest-value targets are products with:

• Multiple strengths and an extended-release form.
• Dense Orange Book listings.
• Prior litigation suggesting claim vulnerability in similar technologies.

Market dynamic: Settlement timing can be as important as patent expiration because the lead time to manufacturing qualification, launch logistics, and payer contract updates often drives real-world market entry.

---

What generic entry risks exist for dopamine agonists: design-around, device constraints, and bioequivalence pitfalls?

Key entry risks in dopamine agonists include:

Design-around risk

• Formulation patents can cover parameter ranges that are difficult to avoid while still meeting dissolution or release specifications.
• Transdermal patents can be hard to design around because drug-in-adhesive or membrane architecture can fall within claim scope.

Bioequivalence and release-profile risk

• Extended-release tablets and transdermal systems must match release behavior and systemic exposure targets.
• If a generic’s release profile is not within the acceptable corridor, FDA may delay approval or require additional studies.

Manufacturing and scale-up risk

• Controlled-release and patch manufacturing can introduce batch-to-batch variability.
• A technical failure at validation can push launch despite patent clearance.

Labeling and method-of-use exposure

• Even after composition/formulation clearance, method-of-use patents can affect label strategy, including where a generic wants to use specific dosing instructions tied to patented claims.

---

How does each dopamine agonist compare on patent estate intensity: extended-release vs IR vs transdermal?

General pattern by delivery form:

• IR tablets: fewer delivery-system patents; generic conversion often faster once base rights expire.
• ER tablets: more formulation and manufacturing patents; generic entry tends to be later.
• Transdermal patches: more delivery-system and device-related claims; generic entry is often delayed and litigation-heavy.

Implication for licensing and investment:

• The most defensible lifecycle positions are typically anchored to ER or transdermal delivery. Those are where assignees tend to build multi-patent estates with overlapping claim coverage.

---

What patent litigation affects dopamine agonists: what to expect in disputes and settlements?

Typical litigation drivers:

• Orange Book patent scope disputes over formulation parameters or release characteristics.
• Infringement and validity fights focused on prior art for formulation or manufacturing methods.
• Claim construction fights that narrow or broaden the relevant claim interpretation.
• Settlement agreements that define carve-outs by dosage form, strength, and launch date.

Market dynamic: Litigation settlements frequently lock in a delayed generic entry in exchange for avoided trial risk. For investors, value is often created by narrowing the number of eligible launch SKUs the settlement covers.

---

How do FDA regulatory pathway and exclusivity interact with the patent clock for dopamine agonists?

For generic development:

• ANDA route is typical for small molecules like pramipexole and ropinirole and for approved generics of related salts or forms where permitted.
• For complex dosage forms, FDA may require additional CMC and in vivo or bridging packages to match the reference release profile.

For branded lifecycle extensions:

• Sponsors often pursue new strengths, new dosage forms, or supplemental indications.
• This can introduce additional Orange Book patents and restart specific regulatory timelines for those supplemental approvals.

Featured snippet answer: In dopamine agonists, FDA pathway milestones determine whether ANDA applicants can capitalize on patent expiration quickly; patent expiration alone does not guarantee immediate market entry.

---

What revenue exposure do generic launches create in the dopamine agonist class?

Revenue exposure is typically high for:

• ER and transdermal SKUs, because payer switching and formulary changes can accelerate once pricing pressure starts.
• Large-volume PD and RLS franchises with multiple strengths and stable prescribing.

However, exposure varies by:

• Patient adherence and tolerability differences across delivery forms.
• Competition among multiple branded offerings within the same class, which can reduce the “cliff” impact.
• Payer contracting and patient support programs that persist even after a generic enters.

Business outcome: The largest near-term revenue downside risk tends to be for the most pharmacist- and PBM-friendly formats, especially ER tablets and transdermal systems.

---

Which formulations are protected by the strongest patent estates in dopamine agonists?

Formulation patents most commonly include:

• Controlled-release matrices and polymer blends.
• Rate-controlling membranes and adhesives for transdermal patches.
• Stability and dissolution-linked formulations that preserve bioavailability.

The strongest estates usually share:

• Many overlapping claims across independent and dependent claims.
• Multiple patent families spanning drug-product and manufacturing process.
• Claims tethered to quantifiable release or dissolution parameters.

Market implication: Generic challengers must either invalidate these patents, litigate claim scope, or design around release profiles while maintaining bioequivalence.

---

Key Takeaways

• Dopamine agonists typically face a “last Orange Book patent” timing logic where formulation, delivery-system, and method-of-use patents matter as much as base active ingredient patents.
• Extended-release and transdermal products usually have denser patent coverage and higher generic entry friction.
• Paragraph IV ANDAs and settlements are the key drivers of real-world entry timing, with manufacturing and bioequivalence risks frequently compounding patent clearance.
• For licensing and investment, the most actionable intelligence is per-dosage-form patent mapping: identify the last listed patents tied to each strength and delivery format, then monitor litigation status and settlement launch terms.

---

FAQs

1) What does “last Orange Book patent” mean for dopamine agonist generic timing?
It is the latest expiration date among Orange Book-listed patents for the specific NDA strength and dosage form; generics cannot launch until they clear all relevant listed patents for that SKU.

2) Which dopamine agonists are most vulnerable to formulation lifecycle challenges?
Extended-release and transdermal versions are typically targeted because their patent estates can include multiple formulation and delivery-system patents that can be challenged or designed around.

3) Do method-of-use patents delay generic approvals of dopamine agonists even when the molecule is off-patent?
Yes when the method-of-use claims are listed and can restrict label matching or require carve-outs tied to the patented dosing/regimen instructions.

4) How do transdermal delivery system patents affect biosimilar-style risk in dopamine agonists?
While biosimilar pathways do not apply to small-molecule dopamine agonists, transdermal delivery system patents function like platform patents, creating analogous design-around difficulty for generic product developers.

5) What settlement terms most influence market entry in dopamine agonist patent cases?
Launch date carve-outs, which strengths or dosage forms are excluded, and any stipulations on product labeling or manufacturing changes that can reduce competitive overlap.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. NLM. (n.d.). MeSH Browser: Dopamine Agonists. National Library of Medicine. https://meshb.nlm.nih.gov/
3. FDA. (n.d.). ANDA: Abbreviated New Drug Application. U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
4. FDA. (n.d.). Patent and Exclusivity. U.S. Food and Drug Administration. https://www.fda.gov/drugs/transactions-patent-and-exclusivity